AstraZeneca’s oral relaxin agonist produced encouraging Phase 2b signals in chronic heart failure, according to coverage of data from ESC 2026. The results reportedly improved measures of cardiac function across two patient groups, adding to the growing pipeline competition in heart failure where endpoints and subgroup activity are critical for later-stage decisions. For AstraZeneca, the readout offers continued validation of the company’s strategy around relaxin biology and could shape the design of subsequent pivotal trials. For clinicians, the next question will be whether the observed functional improvements translate into harder clinical outcomes such as hospitalization or mortality in larger studies. The story is notable for biotech stakeholders tracking cardiology risk-reward, as late-stage planning often hinges on consistent biomarker- and imaging-linked signals rather than a single primary endpoint.